Financial Data and Key Metrics Changes - Group revenues for 2023 were €781.4 million, a 4% increase compared to the previous year, despite significant operational impacts from a cyber incident [42][43] - Adjusted Group EBITDA for the year was €66.4 million, marking a 34% decline from last year, largely due to non-recoverable business and reduced capacity utilization in Q2 [44] - Gross margin declined to 22.6% from 23.2% due to the cyber incident and market challenges, with an adjusted gross margin of 27% excluding Just-Biologics [22][43] Business Line Data and Key Metrics Changes - Revenue from Just-Evotec Biologics reached €108.4 million, reflecting a remarkable increase of over 110% compared to the prior year, driven by strong partnerships [12] - The Innovate segment saw growth of more than 30%, primarily due to contract extensions with BMS in neurodegeneration and target protein degradation [45] - Execute segment revenues grew year-over-year, despite being adversely impacted by the cyber incident and a softening market towards the end of the year [46] Market Data and Key Metrics Changes - The share of biotech in the company's business decreased from approximately 40% to 34% due to fewer new funding events, indicating a challenging environment for biotech companies [39] - The company anticipates a market recovery towards 2025, with a cautious outlook for 2024 due to ongoing challenges in the biotech sector [28][39] Company Strategy and Development Direction - The company is focusing on profitability, efficiency, and high performance, with a strategic reset to align with market demands [9][30] - A new management structure has been introduced, including the appointment of a Chief People Officer to enhance organizational alignment and culture [11] - The company plans to optimize its organizational structure and operational model, with a target of generating annualized EBITDA improvements of over €40 million [79] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges faced in 2023, including a cyber incident that resulted in €70 million in missed revenue, but expressed confidence in the company's ability to recover and grow [21][44] - The outlook for 2024 includes expectations of double-digit revenue growth, with a focus on Just-Evotec Biologics and differentiated offerings [36][80] - Management highlighted the importance of rebuilding momentum in the sales pipeline following the cyber incident and emphasized the need for careful monitoring of market conditions [66][96] Other Important Information - The company has made significant strides in sustainability, reducing Scope 1 and 2 emissions by 29% [23] - The new CEO, Dr. Christian Wojczewski, is expected to lead the company towards a prosperous future, leveraging his experience in transformational change [9][10] Q&A Session Summary Question: What are the expectations for 2024 and 2025? - Management indicated a qualitative guidance for 2024, expecting at least €100 million in EBITDA and €200 million plus in 2025, while acknowledging uncertainties [58][60] Question: What has changed in the market to prompt a more cautious outlook? - Management noted a decline in biotech funding and a challenging environment, leading to a cautious approach despite some early signs of recovery [64][66] Question: How is the order book looking across the broader business? - Management expressed confidence in the order book, indicating a double-digit growing demand and a strong pipeline, particularly in Just-Evotec Biologics [110]

COLLABORATION LEVERAGES VARIANT BIO'S CUTTING-EDGE GENOMIC DISCOVERY PLATFORM AND EVOTEC'S INTEGRATED END-TO-END R&D PLATFORM AND DISEASE AREA EXPERTISE TO ADDRESS UNMET MEDICAL NEED IN FIBROTIC INDICATIONS COMMERCIAL TERMS INCLUDE RESEARCH FUNDING AND MILESTONES AND/OR ROYALTY PAYMENTS TO EVOTEC BASED ON THE OVERALL SUCCESS OF THE PROGRAM HAMBURG, Germany and SEATTLE, April 18, 2024 /PRNewswire/ -- Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and Variant Bio, Inc ...

#researchneverstops | --- | --- | |--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

| --- | --- | --- | |---------------------------------------------------|-------|-------| | | | | | Evotec SE, 9M 2023 results call, 08 November 2023 | | | | --- | --- | |----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

| --- | --- | |---------------------------------|-------| | | | | | | | Emerging stronger | | | Pipeline building gaining speed | | Disclaimer | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

Revenue Performance - Group revenues increased by 14% to €383.8 million in H1 2023, compared to €336.9 million in H1 2022, with like-for-like revenue growth also at 14%[4] - Total EVT Execute revenues rose by 2% to €356.6 million, while EVT Innovate revenues surged by 66% to €129.7 million in H1 2023[4] - Evotec reported a revenue of €383.835 million for the first half of 2023, an increase of 13.9% compared to €336.875 million in the same period of 2022[66] - Total revenues for the first half of 2023 amounted to €383,835k, representing a 14% increase compared to €336,875k in the same period of 2022[78][80] - Service fees and FTE-based research payments contributed €359,971k to total revenues, with a breakdown of €207,641k from Execute and €115,430k from Innovate[78] Financial Guidance - The company confirmed full-year 2023 revenue guidance of €750 – 790 million, with adjusted EBITDA guidance of €60 – 80 million[5] EBITDA and Profitability - Adjusted Group EBITDA for H1 2023 totaled €26.1 million, down from €33.6 million in H1 2022, impacted by a cyber-incident[4] - The company's Adjusted EBITDA for the first half of 2023 was €26.099 million, down from €33.636 million in the first half of 2022, reflecting a decrease of 22.4%[60] - Just – Evotec Biologics contributed an EBITDA of €8.5 million in H1 2023, with Q2 2023 showing a significant recovery to €20.0 million[26] - Net income for the first half of 2023 was a loss of €28.828 million, an improvement from a loss of €101.179 million in the same period of 2022[66] - The company’s total comprehensive income (loss) for the first half of 2023 was a loss of €18,478k, compared to a loss of €107,900k in the first half of 2022, reflecting a 82.9% improvement[69] Expenses and Costs - SG&A expenses increased by 31% to €88.2 million in H1 2023, driven by headcount growth to support business expansion[21] - Adjusted Group EBITDA for H1 2023 was €26.1 million, down from €33.6 million in H1 2022, impacted by a cyber-attack and higher management costs[25] - Cash flow from operating activities was €(5.2) million in H1 2023, a significant decline from €240.6 million in H1 2022, which was boosted by a $200 million upfront payment from BMS[32] Assets and Liabilities - Total assets increased by €44.0 million to €2,301.2 million as of 30 June 2023, with trade and other receivables rising by €30.7 million[37][38] - The company’s total financial assets as of June 30, 2023, were €1,008,060k, with cash and cash equivalents amounting to €459,752k[91] - The Group's total financial liabilities were €1,002,249k as of June 30, 2023, with loans and borrowings at €348,377k[92] - Total stockholders' equity decreased by 1% to €1,174.3 million as of 30 June 2023, with an equity ratio of 51.0%[46] Research and Development - Unpartnered R&D expenses are expected to be in the range of €60 – 70 million for FY 2023, consistent with €70 million in 2022[6] - Significant collaborations include a new agreement with Janssen for oncology therapies, with potential payments exceeding US$350 million over three years[12] - A milestone payment of €2 million was received from Bayer for the first patient dosed in a Phase I study of a kidney disease program[13] - R&D tax credits resulted in other operating income of €20.1 million in H1 2023, slightly up from €19.3 million in H1 2022[23] Cash Flow and Financing - Cash and cash equivalents increased to €459.752 million as of June 30, 2023, compared to €415.155 million at the end of 2022, representing a growth of 10.7%[64] - The company experienced a net cash inflow from financing activities of €10,480k in the first half of 2023, compared to a net outflow of €45,805k in the same period of 2022[68] - The company secured an unsecured loan facility of €150 million from the European Investment Bank to support R&D activities and the construction of a new production facility in Toulouse, France[74] Workforce and Growth - The workforce grew by 2.3% to 5,067 employees as of 30 June 2023, reflecting a net increase of 115 employees in the first half of the year[47] Market Performance - The company’s share price increased by 35% from the end of 2022 to June 30, 2023, significantly outperforming both the TecDAX and MDAX indices by more than 20%[62]

Exhibit 99.1 Notification of Major Holdings 2. Reason for notification (multiple reasons possible) 3. Details of person subject to the notification obligation | Natural person | | | | --- | --- | --- | | First name | Surname | Date of birth | Legal entity | Name including legal form (entity) | City of registered office | Country | | --- | --- | --- | | BlackRock, Inc. | New York, New York | United States of America (the) | Bundesanstalt für Finanzdienstleistungsaufsicht X Notification of Major Holdings or C ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . OR ☐ SHELL COMPANY REPORT PURSUANT TO SE ...

Evotec SE (OTCPK:EVOTF) Q4 2022 Earnings Conference Call March 28, 2023 8:00 AM ET Company Participants Werner Lanthaler - Chief Executive Officer Enno Spillner - Chief Financial Officer Craig Johnstone - Chief Operating Officer Matthias Evers - Chief Business Officer Conference Call Participants Zoe Karamanoli - Royal Bank of Canada Peter Verdult - Citi James Quigley - Morgan Stanley Steven Mah - Cowen Peter Welford - Jefferies Falko Friedrichs - Deutsche Bank Christian Ehmann - Warburg Research Operator L ...

Evotec SE (OTCPK:EVOTF) Q3 2022 Results Conference Call November 9, 2022 8:00 AM ET Company Participants Werner Lanthaler - Chief Executive Officer Enno Spillner - Chief Financial Officer Craig Johnstone - Chief Operating Officer Cord Dohrmann - Chief Scientific Officer Matthias Evers - Chief Business Officer Conference Call Participants Zoe Karamanoli - RBC Capital Markets Christian Ehmann - Warburg Research James Quigley - Morgan Stanley Derik de Bruin - Bank of America Peter Welford - Jefferies Joe Hedde ...